Uncategorized

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Published

on

Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day for the Prader-Willi syndrome community.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version